Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
5.31
+0.15 (2.91%)
Nov 21, 2024, 2:49 PM EST - Market open

Company Description

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.

In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.

The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon, Inc.
Annexon logo
Country United States
Founded 2011
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 71
CEO Douglas Love

Contact Details

Address:
1400 Sierra Point Parkway, Building C
Brisbane, California 94005
United States
Phone 650 822 5500
Website annexonbio.com

Stock Details

Ticker Symbol ANNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001528115
CUSIP Number 03589W102
ISIN Number US03589W1027
Employer ID 27-5414423
SIC Code 2834

Key Executives

Name Position
Douglas Love Esq., J.D. Chief Executive Officer, President and Director
Dr. Dean R. Artis Ph.D. Chief Scientific Officer and Executive Vice President
Dr. Ted Yednock Ph.D. Executive Vice President, Chief Innovation Officer and Chairman of the Scientific Advisory Board
Michael Overdorf M.B.A. Executive Vice President and Chief Business Officer
Henk-Andre Kroon M.D. Senior Vice President of Translational Medicine
Dr. Jamie Dananberg M.D. Executive Vice President and Chief Medical Officer
Shikhar Agarwal M.B.A. Senior Vice President and Head of Commercial
Dr. Sunil Mehta Pharm.D. Senior Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals